Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HNGRNASDAQ:IMACNASDAQ:MRUSNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHNGRHanger$18.72$18.70$13.42▼$22.67$732.38M1.28356,429 shsN/AIMACIMAC$0.03+6.1%$0.09$0.75▼$1.65$874K-0.88708,132 shs8,322 shsMRUSMerus$55.14+32.5%$42.72$33.19▼$61.61$3.82B0.94758,206 shs7.87 million shsSRRKScholar Rock$30.00-1.5%$30.77$6.76▼$46.98$2.89B0.371.27 million shs825,200 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHNGRHanger0.00%0.00%0.00%0.00%0.00%IMACIMAC+6.11%-9.84%-25.00%-94.97%-98.94%MRUSMerus+32.55%+32.68%+31.82%+16.40%+27.05%SRRKScholar Rock-1.51%-1.80%-7.94%-20.42%+156.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHNGRHanger1.2111 of 5 stars0.00.00.04.40.01.71.9IMACIMACN/AN/AN/AN/AN/AN/AN/AN/AMRUSMerus3.215 of 5 stars4.63.00.00.03.31.70.0SRRKScholar Rock3.9788 of 5 stars3.50.00.04.43.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHNGRHanger 0.00N/AN/AN/AIMACIMAC 0.00N/AN/AN/AMRUSMerus 3.13Buy$86.0055.97% UpsideSRRKScholar Rock 3.00Buy$42.6742.22% UpsideCurrent Analyst Ratings BreakdownLatest HNGR, IMAC, MRUS, and SRRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.005/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.004/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/9/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$83.00 ➝ $83.003/28/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/25/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/18/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/17/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/10/2025MRUSMerusBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $70.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHNGRHanger$1.12B0.65$1.88 per share9.98$2.85 per share6.57IMACIMAC$15.22M0.06N/AN/A$0.69 per share0.05MRUSMerus$54.73M69.73N/AN/A$6.17 per share8.94SRRKScholar Rock$33.19M85.82N/AN/A$3.12 per share9.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHNGRHanger$41.98M$0.9519.7115.60N/A3.17%35.72%4.00%N/AIMACIMAC-$10.54MN/A0.00N/AN/A-75.40%-52.17%-34.51%N/AMRUSMerus-$154.94M-$4.08N/AN/AN/A-680.61%-38.89%-31.16%7/30/2025 (Estimated)SRRKScholar Rock-$165.79M-$2.53N/AN/AN/AN/A-145.60%-91.83%N/ALatest HNGR, IMAC, MRUS, and SRRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A2/27/2025Q4 2024MRUSMerus-$0.89-$0.41+$0.48-$0.41$10.57 million$9.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHNGRHangerN/AN/AN/AN/AN/AIMACIMACN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHNGRHanger3.711.230.85IMACIMAC0.011.271.27MRUSMerusN/A8.328.32SRRKScholar Rock0.633.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHNGRHanger79.17%IMACIMAC24.27%MRUSMerus96.14%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipHNGRHanger4.36%IMACIMAC10.00%MRUSMerus4.57%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHNGRHanger5,20039.12 million37.42 millionOptionableIMACIMAC10626.49 million23.84 millionNot OptionableMRUSMerus3769.21 million65.34 millionOptionableSRRKScholar Rock14094.95 million75.64 millionOptionableHNGR, IMAC, MRUS, and SRRK HeadlinesRecent News About These CompaniesBNP Paribas Financial Markets Sells 13,394 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 23 at 3:17 AM | marketbeat.comNationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Purchases New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 22 at 7:39 AM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by Woodline Partners LPMay 22 at 6:18 AM | marketbeat.comSoleus Capital Management L.P. Invests $7.24 Million in Scholar Rock Holding Co. (NASDAQ:SRRK)May 21 at 8:08 AM | marketbeat.comRafferty Asset Management LLC Sells 37,595 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 21 at 5:41 AM | marketbeat.comPolar Asset Management Partners Inc. Trims Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)May 20, 2025 | marketbeat.comDimensional Fund Advisors LP Lowers Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 20, 2025 | marketbeat.comHC Wainwright Boosts Earnings Estimates for Scholar RockMay 20, 2025 | marketbeat.comWedbush Forecasts Scholar Rock's Q2 Earnings (NASDAQ:SRRK)May 20, 2025 | americanbankingnews.comWhat is Wedbush's Estimate for Scholar Rock Q2 Earnings?May 20, 2025 | marketbeat.comDeutsche Bank AG Has $8 Million Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)May 19, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Stock Holdings Lessened by Sphera Funds Management LTD.May 18, 2025 | marketbeat.comWhat is Wedbush's Forecast for Scholar Rock FY2029 Earnings?May 18, 2025 | americanbankingnews.comPolar Capital Holdings Plc Reduces Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 17, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Acquired by Janus Henderson Group PLCMay 17, 2025 | marketbeat.comScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2025 | businesswire.comMPM Bioimpact LLC Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 16, 2025 | marketbeat.com400,000 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Acquired by Paradigm Biocapital Advisors LPMay 16, 2025 | marketbeat.comPatient Square Capital LP Purchases New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 16, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by Ensign Peak Advisors IncMay 16, 2025 | marketbeat.comBaird Financial Group Inc. Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHNGR, IMAC, MRUS, and SRRK Company DescriptionsHanger NYSE:HNGRHanger, Inc. provides orthotic and prosthetic (O&P) services in the United States. It operates in two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and offers payor network contracting services to other O&P providers. The Products & Services segment engages in the distribution of various O&P parts, componentry, and devices to independent O&P providers; development of specialized rehabilitation technologies; and provision of evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2021, the company operated approximately 760 patient care clinics and 115 satellite locations in 47 states and the District of Columbia. It also distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings. The company was formerly known as Hanger Orthopedic Group, Inc. and changed its name to Hanger, Inc. in June 2012. Hanger, Inc. was founded in 1861 and is headquartered in Austin, Texas.IMAC NASDAQ:IMAC$0.03 +0.00 (+6.11%) As of 05/22/2025IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.Merus NASDAQ:MRUS$55.14 +13.54 (+32.55%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$54.95 -0.19 (-0.34%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Scholar Rock NASDAQ:SRRK$30.00 -0.46 (-1.51%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$29.68 -0.32 (-1.05%) As of 05/23/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
